320 related articles for article (PubMed ID: 32709853)
21. Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.
Boerner JL; Nechiporchik N; Mueller KL; Polin L; Heilbrun L; Boerner SA; Zoratti GL; Stark K; LoRusso PM; Burger A
PLoS One; 2015; 10(3):e0119614. PubMed ID: 25774912
[TBL] [Abstract][Full Text] [Related]
22. Development and some characteristics of a P388 leukemia strain resistant to 1, 2:5, 6-dianhydrogalactitol.
Bence J; Somfai-Relle S; Gáti E
Eur J Cancer Clin Oncol; 1986 Jul; 22(7):773-80. PubMed ID: 3770035
[TBL] [Abstract][Full Text] [Related]
23. Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells.
Goldwasser F; Shimizu T; Jackman J; Hoki Y; O'Connor PM; Kohn KW; Pommier Y
Cancer Res; 1996 Oct; 56(19):4430-7. PubMed ID: 8813137
[TBL] [Abstract][Full Text] [Related]
24. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication.
Aghi M; Rabkin S; Martuza RL
J Natl Cancer Inst; 2006 Jan; 98(1):38-50. PubMed ID: 16391370
[TBL] [Abstract][Full Text] [Related]
25. Adenovirus-mediated E2F-1 gene transfer sensitizes melanoma cells to apoptosis induced by topoisomerase II inhibitors.
Dong YB; Yang HL; Elliott MJ; McMasters KM
Cancer Res; 2002 Mar; 62(6):1776-83. PubMed ID: 11912154
[TBL] [Abstract][Full Text] [Related]
26. Sensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparib.
Augustine T; Maitra R; Zhang J; Nayak J; Goel S
Invest New Drugs; 2019 Oct; 37(5):948-960. PubMed ID: 30612311
[TBL] [Abstract][Full Text] [Related]
27. A novel oral camptothecin analog, gimatecan, exhibits superior antitumor efficacy than irinotecan toward esophageal squamous cell carcinoma in vitro and in vivo.
Zou J; Li S; Chen Z; Lu Z; Gao J; Zou J; Lin X; Li Y; Zhang C; Shen L
Cell Death Dis; 2018 May; 9(6):661. PubMed ID: 29855512
[TBL] [Abstract][Full Text] [Related]
28. CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo.
Tse AN; Rendahl KG; Sheikh T; Cheema H; Aardalen K; Embry M; Ma S; Moler EJ; Ni ZJ; Lopes de Menezes DE; Hibner B; Gesner TG; Schwartz GK
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):591-602. PubMed ID: 17255282
[TBL] [Abstract][Full Text] [Related]
29. Guanidine-reactive agent phenylglyoxal induces DNA damage and cancer cell death.
Calderón-Montaño JM; Burgos-Morón E; Orta ML; Pastor N; Perez-Guerrero C; Austin CA; Mateos S; López-Lázaro M
Pharmacol Rep; 2012; 64(6):1515-25. PubMed ID: 23406762
[TBL] [Abstract][Full Text] [Related]
30. Simultaneous targeting of DNA replication and homologous recombination in glioblastoma with a polyether ionophore.
Lim YC; Ensbey KS; Offenhäuser C; D'souza RCJ; Cullen JK; Stringer BW; Quek H; Bruce ZC; Kijas A; Cianfanelli V; Mahboubi B; Smith F; Jeffree RL; Wiesmüeller L; Wiegmans AP; Bain A; Lombard FJ; Roberts TL; Khanna KK; Lavin MF; Kim B; Hamerlik P; Johns TG; Coster MJ; Boyd AW; Day BW
Neuro Oncol; 2020 Feb; 22(2):216-228. PubMed ID: 31504812
[TBL] [Abstract][Full Text] [Related]
31. Different modes of cell-killing action between DNA topoisomerase I and II inhibitors revealed by kinetic analysis.
Inaba M; Mitsuhashi J; Kawada S; Nakano H
Jpn J Cancer Res; 1994 Feb; 85(2):187-93. PubMed ID: 8144400
[TBL] [Abstract][Full Text] [Related]
32. Etoposide-induced cell cycle delay and arrest-dependent modulation of DNA topoisomerase II in small-cell lung cancer cells.
Smith PJ; Souès S; Gottlieb T; Falk SJ; Watson JV; Osborne RJ; Bleehen NM
Br J Cancer; 1994 Nov; 70(5):914-21. PubMed ID: 7947097
[TBL] [Abstract][Full Text] [Related]
33. Selective killing of G2 decatenation checkpoint defective colon cancer cells by catalytic topoisomerase II inhibitor.
Jain CK; Roychoudhury S; Majumder HK
Biochim Biophys Acta; 2015 May; 1853(5):1195-204. PubMed ID: 25746763
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapeutic approaches to brain tumors. Experimental observations with dianhydrogalactitol and dibromodulcitol.
Levin VA; Wheeler KT
Cancer Chemother Pharmacol; 1982; 8(1):125-31. PubMed ID: 7094198
[TBL] [Abstract][Full Text] [Related]
35. Perturbed cell kinetics of 9L rat brain tumor cells following dianhydrogalactitol.
Nomura K; Hoshino T; Deen DF; Knebel KD
Cancer Treat Rep; 1978 Dec; 62(12):2055-61. PubMed ID: 751715
[TBL] [Abstract][Full Text] [Related]
36. p21CDKN1A allows the repair of replication-mediated DNA double-strand breaks induced by topoisomerase I and is inactivated by the checkpoint kinase inhibitor 7-hydroxystaurosporine.
Furuta T; Hayward RL; Meng LH; Takemura H; Aune GJ; Bonner WM; Aladjem MI; Kohn KW; Pommier Y
Oncogene; 2006 May; 25(20):2839-49. PubMed ID: 16407843
[TBL] [Abstract][Full Text] [Related]
37. Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models.
Wise HC; Iyer GV; Moore K; Temkin SM; Gordon S; Aghajanian C; Grisham RN
Sci Rep; 2019 Dec; 9(1):18882. PubMed ID: 31827119
[TBL] [Abstract][Full Text] [Related]
38. Gap-filling and bypass at the replication fork are both active mechanisms for tolerance of low-dose ultraviolet-induced DNA damage in the human genome.
Quinet A; Vessoni AT; Rocha CR; Gottifredi V; Biard D; Sarasin A; Menck CF; Stary A
DNA Repair (Amst); 2014 Feb; 14():27-38. PubMed ID: 24380689
[TBL] [Abstract][Full Text] [Related]
39. Differential effects of caffeine on DNA damage and replication cell cycle checkpoints in the fission yeast Schizosaccharomyces pombe.
Osman F; McCready S
Mol Gen Genet; 1998 Nov; 260(4):319-34. PubMed ID: 9870697
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of FGFR2-Signaling Attenuates a Homology-Mediated DNA Repair in GIST and Sensitizes Them to DNA-Topoisomerase II Inhibitors.
Sergei B; Pavel D; Aigul G; Firyuza B; Ilmira N; Ilshat M; Aida A; Refat K; Natalia A; Elena S; Vera G
Int J Mol Sci; 2020 Jan; 21(1):. PubMed ID: 31948066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
